sumatriptan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives	2543	103628-46-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: GR43175 GR 43175 sumatriptan sumatriptan succinate	A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS. Molecular weight: 295.40 Formula: C14H21N3O2S CLOGP: 0.74 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 65.20 ALOGS: -3.37 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

GR43175
GR 43175
sumatriptan
sumatriptan succinate

A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.

Molecular weight: 295.40
Formula: C14H21N3O2S
CLOGP: 0.74
LIPINSKI: 0
HAC: 5
HDO: 2
TPSA: 65.20
ALOGS: -3.37
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	N
50	mg	O
6	mg	P
25	mg	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	21.40 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	22 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.68 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	14 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.70 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	19 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.83 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.70 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 28, 1992	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product physical issue	4071.35	11.48	911	48705	4069	63435337
Product dose omission issue	1058.50	11.48	1097	48519	233216	63206190
Application site erythema	566.34	11.48	192	49424	4643	63434763
Migraine	536.74	11.48	523	49093	102823	63336583
Product quality issue	495.46	11.48	323	49293	35542	63403864
Application site burn	379.03	11.48	95	49521	739	63438667
Device deployment issue	334.96	11.48	123	49493	3779	63435627
Application site pain	326.65	11.48	123	49493	4059	63435347
Device malfunction	323.01	11.48	191	49425	17666	63421740
Application site discolouration	263.85	11.48	71	49545	750	63438656
Device issue	254.41	11.48	183	49433	23598	63415808
Application site paraesthesia	195.20	11.48	36	49580	39	63439367
Accidental exposure to product	151.98	11.48	144	49472	27261	63412145
Application site urticaria	139.91	11.48	34	49582	229	63439177
Application site rash	133.94	11.48	56	49560	2442	63436964
Medication overuse headache	133.73	11.48	42	49574	790	63438616
Headache	126.46	11.48	886	48730	632355	62807051
Application site irritation	124.18	11.48	48	49568	1702	63437704
Arteriospasm coronary	120.89	11.48	60	49556	3908	63435498
Colitis ischaemic	115.86	11.48	83	49533	10625	63428781
Application site warmth	113.22	11.48	27	49589	166	63439240
Application site pruritus	111.86	11.48	57	49559	3927	63435479
Coronary artery dissection	103.95	11.48	35	49581	827	63438579
Glossodynia	100.99	11.48	11	49605	178865	63260541
Anxiety	96.91	11.48	381	49235	217160	63222246
Systemic lupus erythematosus	93.45	11.48	24	49592	208894	63230512
Arthropathy	89.08	11.48	36	49580	234756	63204650
Serotonin syndrome	89.07	11.48	111	49505	28571	63410835
Injection site pain	88.31	11.48	262	49354	129538	63309868
Wound	85.03	11.48	13	49603	163250	63276156
Application site scar	83.48	11.48	22	49594	213	63439193
Needle issue	82.63	11.48	67	49549	10309	63429097
Contraindicated product administered	81.54	11.48	34	49582	217614	63221792
Death	81.37	11.48	104	49512	374277	63065129
Application site vesicles	79.73	11.48	33	49583	1402	63438004
Injection site haemorrhage	78.57	11.48	96	49520	24218	63415188
Infusion related reaction	76.19	11.48	49	49567	245472	63193934
Product complaint	74.25	11.48	69	49547	12740	63426666
Throat tightness	73.60	11.48	94	49522	24793	63414613
Application site swelling	71.80	11.48	24	49592	554	63438852
Reversible cerebral vasoconstriction syndrome	71.65	11.48	37	49579	2621	63436785
Drug ineffective	70.53	11.48	1175	48441	1043590	62395816
Product substitution issue	70.13	11.48	74	49542	15922	63423484
Depression	69.54	11.48	321	49295	196171	63243235
Wrong technique in product usage process	68.64	11.48	151	49465	62189	63377217
IIIrd nerve paresis	68.07	11.48	17	49599	130	63439276
Paraesthesia	66.70	11.48	271	49345	156695	63282711
Endometriosis	66.35	11.48	45	49571	5275	63434131
Treatment failure	64.13	11.48	38	49578	199005	63240401
Device power source issue	63.68	11.48	22	49594	563	63438843
Emotional distress	62.39	11.48	100	49516	32449	63406957
Acute kidney injury	61.62	11.48	69	49547	263346	63176060
Joint swelling	61.35	11.48	101	49515	327565	63111841
Cerebral vasoconstriction	61.16	11.48	26	49590	1182	63438224
Abdominal discomfort	59.99	11.48	99	49517	320786	63118620
Muscle twitching	59.29	11.48	75	49541	19593	63419813
Anaemia	58.20	11.48	87	49529	293343	63146063
Chest discomfort	55.86	11.48	201	49415	109768	63329638
Lower respiratory tract infection	55.78	11.48	17	49599	132290	63307116
Application site dryness	55.77	11.48	15	49601	158	63439248
Application site reaction	54.74	11.48	21	49595	729	63438677
Cholecystitis chronic	54.69	11.48	53	49563	10308	63429098
Swelling	54.27	11.48	82	49534	275296	63164110
Concussion	53.97	11.48	50	49566	9194	63430212
Rheumatoid arthritis	53.55	11.48	72	49544	253747	63185659
Application site exfoliation	53.04	11.48	18	49598	436	63438970
Injection site bruising	52.48	11.48	107	49509	41803	63397603
Product leakage	52.41	11.48	21	49595	820	63438586
Hepatic enzyme increased	51.83	11.48	49	49567	202279	63237127
Dizziness	51.69	11.48	538	49078	429387	63010019
Pituitary tumour benign	51.56	11.48	27	49589	1968	63437438
Alopecia	51.07	11.48	118	49498	337418	63101988
Post-traumatic neck syndrome	50.58	11.48	27	49589	2047	63437359
Incorrect dose administered by device	50.03	11.48	35	49581	4313	63435093
Application site scab	49.37	11.48	14	49602	182	63439224
Somnambulism	48.86	11.48	38	49578	5505	63433901
Clonus	48.02	11.48	35	49581	4601	63434805
Feeling abnormal	47.80	11.48	236	49380	148156	63291250
Hostility	47.43	11.48	25	49591	1847	63437559
Renal infarct	47.42	11.48	23	49593	1424	63437982
Drug specific antibody	47.37	11.48	27	49589	2328	63437078
Febrile neutropenia	46.81	11.48	17	49599	118432	63320974
Cardiac failure	46.62	11.48	7	49609	89135	63350271
Libido increased	45.96	11.48	22	49594	1323	63438083
Neutropenia	45.27	11.48	42	49574	174963	63264443
Expired product administered	45.22	11.48	38	49578	6143	63433263
Disease progression	44.63	11.48	20	49596	122738	63316668
Device leakage	44.59	11.48	40	49576	7056	63432350
Soft tissue injury	44.54	11.48	23	49593	1629	63437777
Stress cardiomyopathy	43.72	11.48	45	49571	9405	63430001
Synovitis	43.65	11.48	49	49567	186869	63252537
Folliculitis	43.26	11.48	3	49613	70314	63369092
General physical health deterioration	42.60	11.48	57	49559	201345	63238061
Incorrect route of product administration	41.61	11.48	76	49540	27376	63412030
Suicidal ideation	41.46	11.48	125	49491	62296	63377110
Peripheral swelling	40.18	11.48	93	49523	265849	63173557
Application site inflammation	39.92	11.48	14	49602	375	63439031
Swollen tongue	39.09	11.48	85	49531	34715	63404691
Application site bruise	38.22	11.48	13	49603	317	63439089
Off label use	37.94	11.48	341	49275	674121	62765285
Sternal fracture	37.86	11.48	23	49593	2231	63437175
Pre-existing condition improved	37.68	11.48	39	49577	8205	63431201
Product use issue	37.60	11.48	72	49544	220448	63218958
Vasospasm	37.25	11.48	16	49600	746	63438660
Nausea	36.33	11.48	898	48718	853573	62585833
Angle closure glaucoma	35.63	11.48	22	49594	2197	63437209
Nightmare	35.46	11.48	58	49558	19136	63420270
Hot flush	35.45	11.48	104	49512	51055	63388351
Atrial fibrillation	33.85	11.48	25	49591	116611	63322795
Impaired healing	33.83	11.48	19	49597	102523	63336883
Pancytopenia	33.39	11.48	17	49599	96916	63342490
Secondary adrenocortical insufficiency	33.17	11.48	18	49598	1410	63437996
Renal impairment	32.74	11.48	14	49602	88341	63351065
Therapeutic response unexpected	32.40	11.48	55	49561	18704	63420702
Haemoglobin decreased	31.96	11.48	40	49576	145445	63293961
Tremor	31.61	11.48	194	49422	132045	63307361
Infection	31.59	11.48	84	49532	229089	63210317
Hyponatraemia	31.18	11.48	25	49591	111875	63327531
Muscle tightness	30.63	11.48	42	49574	11858	63427548
Diarrhoea	29.27	11.48	389	49227	714977	62724429
Rash	29.17	11.48	289	49327	560582	62878824
Pharyngeal swelling	28.74	11.48	30	49586	6374	63433032
Neonatal respiratory distress	28.62	11.48	11	49605	384	63439022
Hyperprolactinaemia	28.58	11.48	24	49592	3876	63435530
Application site discomfort	28.54	11.48	11	49605	387	63439019
Hypotension	28.49	11.48	113	49503	272491	63166915
Pneumonia	28.29	11.48	225	49391	456542	62982864
Tension headache	28.26	11.48	27	49589	5159	63434247
Chest pain	28.15	11.48	275	49341	215684	63223722
Interstitial lung disease	27.87	11.48	7	49609	61901	63377505
Application site erosion	27.86	11.48	9	49607	186	63439220
Dysgeusia	27.75	11.48	90	49526	46620	63392786
Renal tubular acidosis	27.74	11.48	17	49599	1675	63437731
Malignant neoplasm progression	27.40	11.48	15	49601	82106	63357300
Cerebral venous thrombosis	26.96	11.48	18	49598	2056	63437350
Hip arthroplasty	26.69	11.48	3	49613	47643	63391763
Hyperkalaemia	26.69	11.48	5	49611	54198	63385208
Stomatitis	26.63	11.48	42	49574	138683	63300723
Blood creatinine increased	26.58	11.48	18	49598	87826	63351580
Transient global amnesia	26.19	11.48	12	49604	653	63438753
Vision blurred	25.97	11.48	141	49475	91783	63347623
Cluster headache	25.66	11.48	12	49604	685	63438721
Eyelid ptosis	25.62	11.48	30	49586	7237	63432169
Narcolepsy	25.59	11.48	15	49601	1363	63438043
Drug-disease interaction	25.53	11.48	11	49605	517	63438889
Device defective	25.43	11.48	17	49599	1945	63437461
Platelet count decreased	25.43	11.48	32	49584	116090	63323316
Migraine without aura	25.14	11.48	10	49606	383	63439023
Liver injury	25.10	11.48	8	49608	60512	63378894
Poor quality sleep	25.07	11.48	51	49565	19884	63419522
Pleural effusion	24.53	11.48	22	49594	93188	63346218
Photophobia	24.45	11.48	47	49569	17588	63421818
Vasoconstriction	24.25	11.48	11	49605	585	63438821
Somnolence	24.00	11.48	229	49387	178456	63260950
Nipple pain	23.83	11.48	9	49607	299	63439107
Injection site laceration	23.82	11.48	7	49609	104	63439302
Multiple sclerosis	23.46	11.48	56	49560	24316	63415090
Swelling face	23.37	11.48	105	49511	63370	63376036
C-reactive protein abnormal	23.24	11.48	4	49612	46092	63393314
Oxygen saturation decreased	23.20	11.48	21	49595	88564	63350842
Gastrointestinal haemorrhage	22.79	11.48	18	49598	81158	63358248
Sepsis	22.74	11.48	54	49562	153069	63286337
Hypoaesthesia	22.70	11.48	216	49400	168177	63271229
Discomfort	22.56	11.48	62	49554	167312	63272094
Blister	22.45	11.48	42	49574	129772	63309634
Palpitations	22.42	11.48	158	49458	112612	63326794
Muscle spasms	21.90	11.48	202	49414	155948	63283458
Red blood cell sedimentation rate increased	21.78	11.48	4	49612	43978	63395428
Hyperreflexia	21.76	11.48	25	49591	5909	63433497
Application site papules	21.60	11.48	6	49610	72	63439334
Hyperhidrosis	21.38	11.48	151	49465	107685	63331721
Septic shock	21.05	11.48	13	49603	66616	63372790
Decreased appetite	20.92	11.48	113	49503	250939	63188467
Drug hypersensitivity	20.91	11.48	350	49266	310337	63129069
Seizure	20.89	11.48	176	49440	132458	63306948
Blood testosterone increased	20.88	11.48	7	49609	163	63439243
Neck pain	20.72	11.48	108	49508	69210	63370196
Irritability	20.60	11.48	63	49553	31631	63407775
Personality disorder	20.50	11.48	24	49592	5787	63433619
Middle insomnia	20.43	11.48	36	49580	12607	63426799
Thrombocytopenia	20.37	11.48	56	49560	151101	63288305
Migraine with aura	20.36	11.48	17	49599	2723	63436683
Pyrexia	20.23	11.48	253	49363	470225	62969181
Major depression	20.19	11.48	28	49588	7990	63431416
Injection site injury	20.08	11.48	10	49606	656	63438750
Dependence	19.98	11.48	15	49601	2062	63437344
Meningoradiculitis	19.84	11.48	6	49610	99	63439307
Cardiac failure congestive	19.69	11.48	26	49590	92407	63346999
Knee arthroplasty	19.43	11.48	9	49607	54197	63385209
Optic ischaemic neuropathy	19.33	11.48	12	49604	1210	63438196
Large intestinal ulcer haemorrhage	19.25	11.48	6	49610	110	63439296
Product adhesion issue	19.22	11.48	21	49595	4698	63434708
Post-traumatic stress disorder	19.05	11.48	22	49594	5229	63434177
Sleep talking	18.91	11.48	11	49605	985	63438421
Phonophobia	18.89	11.48	8	49608	360	63439046
Spleen congestion	18.81	11.48	6	49610	119	63439287
Basilar migraine	18.74	11.48	5	49611	51	63439355
Renal failure	18.68	11.48	40	49576	117612	63321794
Biliary dyskinesia	18.38	11.48	16	49600	2713	63436693
Plasma cell myeloma	18.36	11.48	3	49613	35902	63403504
Underdose	18.24	11.48	55	49561	27401	63412005
Sunburn	18.08	11.48	16	49600	2772	63436634
Multiple organ dysfunction syndrome	18.03	11.48	11	49605	56741	63382665
Hyperacusis	17.58	11.48	14	49602	2099	63437307
Incorrect product administration duration	17.54	11.48	32	49584	11514	63427892
Device use error	17.41	11.48	22	49594	5739	63433667
Gastrointestinal disorder	17.40	11.48	49	49567	131190	63308216
Gastrooesophageal reflux disease	17.29	11.48	131	49485	95508	63343898
Complement factor C4 decreased	17.24	11.48	7	49609	283	63439123
Drug dependence	17.17	11.48	50	49566	24433	63414973
Pharyngeal oedema	17.13	11.48	35	49581	13686	63425720
Complement factor C3 decreased	17.06	11.48	7	49609	291	63439115
Meconium in amniotic fluid	17.03	11.48	7	49609	292	63439114
Burns third degree	16.97	11.48	7	49609	295	63439111
Subclavian artery thrombosis	16.69	11.48	6	49610	173	63439233
Application site dermatitis	16.47	11.48	6	49610	180	63439226
Cough	16.38	11.48	148	49468	292595	63146811
Depressive symptom	16.27	11.48	18	49598	4084	63435322
Multiple sclerosis relapse	16.23	11.48	78	49538	48400	63391006
Paraesthesia oral	16.17	11.48	42	49574	19214	63420192
Bipolar disorder	16.00	11.48	25	49591	7935	63431471
Ischaemic cerebral infarction	15.87	11.48	11	49605	1335	63438071
Osteonecrosis of jaw	15.75	11.48	4	49612	35119	63404287
Superior sagittal sinus thrombosis	15.72	11.48	9	49607	782	63438624
Transverse sinus thrombosis	15.71	11.48	8	49608	550	63438856
Rash maculo-papular	15.58	11.48	3	49613	31893	63407513
Ill-defined disorder	15.45	11.48	25	49591	81730	63357676
Pulmonary fibrosis	15.24	11.48	6	49610	39803	63399603
Hepatotoxicity	15.17	11.48	5	49611	37036	63402370
Withdrawal syndrome	15.16	11.48	42	49574	19955	63419451
Illness	15.05	11.48	77	49539	48982	63390424
Neoplasm progression	14.78	11.48	5	49611	36423	63402983
Inflammation	14.77	11.48	26	49590	82247	63357159
International normalised ratio increased	14.74	11.48	9	49607	46416	63392990
Therapeutic product effect decreased	14.46	11.48	90	49526	193097	63246309
Burning sensation	14.39	11.48	82	49534	54325	63385081
Injury associated with device	14.39	11.48	16	49600	3650	63435756
Lichen planus	14.34	11.48	13	49603	2325	63437081
Pericardial effusion	14.32	11.48	3	49613	30055	63409351
Lactic acidosis	14.29	11.48	6	49610	38281	63401125
Peripheral nerve injury	14.27	11.48	7	49609	444	63438962
Hypotonia neonatal	14.27	11.48	10	49606	1236	63438170
Cerebral venous sinus thrombosis	14.17	11.48	12	49604	1960	63437446
Teratogenicity	14.15	11.48	6	49610	271	63439135
Potassium wasting nephropathy	14.11	11.48	4	49612	52	63439354
Nasal discomfort	14.10	11.48	18	49598	4742	63434664
Influenza like illness	14.09	11.48	95	49521	66729	63372677
Loss of personal independence in daily activities	13.90	11.48	35	49581	97255	63342151
Cholestasis	13.90	11.48	3	49613	29431	63409975
Drug ineffective for unapproved indication	13.80	11.48	58	49558	34005	63405401
Bone marrow failure	13.80	11.48	3	49613	29287	63410119
Pancreatic failure	13.75	11.48	9	49607	994	63438412
Loss of consciousness	13.74	11.48	147	49469	117974	63321432
Gallbladder disorder	13.72	11.48	39	49577	18803	63420603
Trismus	13.63	11.48	16	49600	3869	63435537
Hepatic function abnormal	13.57	11.48	6	49610	37136	63402270
Pneumonia aspiration	13.57	11.48	5	49611	34535	63404871
Psoriasis	13.48	11.48	115	49501	86842	63352564
Post viral fatigue syndrome	13.37	11.48	6	49610	311	63439095
Body temperature increased	13.30	11.48	61	49555	37131	63402275
Nasopharyngitis	13.17	11.48	131	49485	254126	63185280
Angioedema	13.15	11.48	73	49543	47892	63391514
Gallbladder injury	13.08	11.48	10	49606	1413	63437993
Toxicity to various agents	12.97	11.48	127	49489	247123	63192283
Injection site erythema	12.89	11.48	110	49506	83064	63356342
Dysphonia	12.75	11.48	72	49544	47542	63391864
Sensory disturbance	12.71	11.48	31	49585	13641	63425765
Melaena	12.61	11.48	4	49612	30361	63409045
Premature delivery	12.56	11.48	4	49612	30277	63409129
Flushing	12.54	11.48	101	49515	74986	63364420
Oedema	12.53	11.48	37	49579	97585	63341821
Arterial intramural haematoma	12.50	11.48	3	49613	19	63439387
Slow speech	12.44	11.48	10	49606	1519	63437887
Tinnitus	12.42	11.48	58	49558	35570	63403836
Meningitis aseptic	12.38	11.48	17	49599	4806	63434600
Product administration interrupted	12.34	11.48	17	49599	4819	63434587
Osteoarthritis	12.34	11.48	36	49580	95307	63344099
Memory impairment	12.24	11.48	130	49486	104128	63335278
Therapeutic response shortened	12.18	11.48	28	49588	11860	63427546
Mobility decreased	12.15	11.48	51	49565	121108	63318298
Alanine aminotransferase increased	12.15	11.48	41	49575	103729	63335677
Rib fracture	12.05	11.48	42	49574	22555	63416851
Ovarian neoplasm	12.05	11.48	8	49608	905	63438501
Deep vein thrombosis	12.04	11.48	109	49507	83691	63355715
Foetal heart rate abnormal	12.00	11.48	7	49609	630	63438776
Maternal exposure during pregnancy	11.98	11.48	112	49504	219950	63219456
Product storage error	11.92	11.48	32	49584	14924	63424482
Device difficult to use	11.88	11.48	29	49587	12767	63426639
Blood cholesterol increased	11.81	11.48	36	49580	93996	63345410
Dysmenorrhoea	11.73	11.48	15	49601	3958	63435448
Chemical burn	11.70	11.48	6	49610	419	63438987
Type 2 diabetes mellitus	11.63	11.48	20	49596	63848	63375558
Arthralgia	11.58	11.48	348	49268	569362	62870044
Drug effect less than expected	11.57	11.48	10	49606	1679	63437727
Cholelithiasis	11.48	11.48	66	49550	43859	63395547

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product physical issue	967.79	17.42	199	7703	2342	34946687
Product dose omission issue	243.30	17.42	207	7695	119504	34829525
Migraine	124.03	17.42	66	7836	17412	34931617
Product quality issue	122.79	17.42	65	7837	16970	34932059
Headache	91.76	17.42	163	7739	200472	34748557
Device deployment issue	91.23	17.42	18	7884	167	34948862
Arteriospasm coronary	80.91	17.42	30	7872	3352	34945677
Coronary artery dissection	60.29	17.42	14	7888	295	34948734
Device malfunction	59.18	17.42	34	7868	10387	34938642
Device issue	53.13	17.42	31	7871	9746	34939283
Throat tightness	52.14	17.42	29	7873	8329	34940700
Serotonin syndrome	51.93	17.42	40	7862	19893	34929136
Medication overuse headache	47.45	17.42	10	7892	132	34948897
IIIrd nerve paresis	43.89	17.42	9	7893	103	34948926
Hyperhidrosis	39.01	17.42	65	7837	75627	34873402
Accidental exposure to product	38.48	17.42	28	7874	12774	34936255
Brugada syndrome	34.36	17.42	11	7891	790	34948239
Cluster headache	33.72	17.42	10	7892	556	34948473
Injection site pain	32.45	17.42	42	7860	38963	34910066
Application site pain	31.72	17.42	13	7889	1895	34947134
Myofascial pain syndrome	28.43	17.42	8	7894	369	34948660
Xanthelasma	27.45	17.42	6	7896	95	34948934
Application site burn	27.43	17.42	7	7895	221	34948808
Foetal exposure during pregnancy	27.07	17.42	38	7864	38063	34910966
Acute kidney injury	26.94	17.42	18	7884	304970	34644059
Anophthalmos	26.81	17.42	4	7898	4	34949025
Drug ineffective	26.57	17.42	185	7717	456566	34492463
Congenital genital malformation male	25.19	17.42	4	7898	8	34949021
Gastrointestinal tract irritation	25.13	17.42	7	7895	311	34948718
Needle issue	24.46	17.42	16	7886	6149	34942880
Craniosynostosis	23.89	17.42	7	7895	373	34948656
Foetal malnutrition	23.52	17.42	5	7897	69	34948960
Death	23.09	17.42	34	7868	398015	34551014
Autonomic dysreflexia	23.07	17.42	5	7897	76	34948953
Chest pain	22.19	17.42	71	7831	126691	34822338
Electrocardiogram ST segment elevation	21.78	17.42	14	7888	5224	34943805
Capillaritis	20.99	17.42	5	7897	118	34948911
Anaemia	20.27	17.42	14	7888	233321	34715708
Muscle tightness	20.17	17.42	13	7889	4871	34944158
Application site erythema	19.95	17.42	10	7892	2326	34946703
Chest discomfort	19.46	17.42	40	7862	54490	34894539
Paraesthesia	19.39	17.42	44	7858	64128	34884901
Aphasia	19.25	17.42	24	7878	21430	34927599
Tobacco abuse	18.62	17.42	6	7896	440	34948589
Irritable bowel syndrome	18.34	17.42	11	7891	3632	34945397
Facial pain	18.17	17.42	11	7891	3693	34945336
Oromandibular dystonia	17.94	17.42	6	7896	495	34948534
Injection site haemorrhage	17.91	17.42	16	7886	9752	34939277
Cleft lip and palate	17.88	17.42	7	7895	905	34948124
Pityriasis lichenoides et varioliformis acuta	17.79	17.42	3	7899	10	34949019
Renal failure	17.56	17.42	4	7898	130553	34818476
Acute myocardial infarction	17.54	17.42	38	7864	53681	34895348

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product physical issue	1313.30	11.71	329	42716	3856	79697487
Migraine	557.66	11.71	425	42620	87068	79614275
Application site erythema	404.92	11.71	138	42907	4972	79696371
Product dose omission issue	339.91	11.71	533	42512	247004	79454339
Application site burn	285.44	11.71	71	42974	804	79700539
Application site pain	236.52	11.71	91	42954	4656	79696687
Product quality issue	231.79	11.71	172	42873	33768	79667575
Headache	195.28	11.71	782	42263	652990	79048353
Application site discolouration	188.92	11.71	51	42994	813	79700530
Arteriospasm coronary	186.86	11.71	85	42960	6631	79694712
Application site paraesthesia	182.88	11.71	32	43013	40	79701303
Device malfunction	179.39	11.71	123	42922	21325	79680018
Coronary artery dissection	157.26	11.71	47	42998	1097	79700246
Accidental exposure to product	148.16	11.71	128	42917	31194	79670149
Medication overuse headache	145.26	11.71	42	43003	870	79700473
Throat tightness	117.94	11.71	107	42938	27800	79673543
Serotonin syndrome	117.50	11.71	133	42912	44894	79656449
IIIrd nerve paresis	116.96	11.71	26	43019	172	79701171
Acute kidney injury	111.00	11.71	72	42973	519332	79182011
Colitis ischaemic	109.70	11.71	80	42965	15279	79686064
Anxiety	102.56	11.71	331	42714	248181	79453162
Application site pruritus	102.15	11.71	47	42998	3763	79697580
Application site irritation	99.80	11.71	37	43008	1707	79699636
Application site warmth	99.20	11.71	23	43022	188	79701155
Device deployment issue	96.82	11.71	43	43002	3169	79698174
Application site urticaria	90.38	11.71	22	43023	226	79701117
Application site rash	89.11	11.71	36	43009	2096	79699247
Death	86.90	11.71	107	42938	566407	79134936
Reversible cerebral vasoconstriction syndrome	86.01	11.71	39	43006	3018	79698325
Endometriosis	85.25	11.71	41	43004	3627	79697716
Paraesthesia	84.00	11.71	247	42798	176076	79525267
Wrong technique in product usage process	80.90	11.71	144	42901	73731	79627612
Anaemia	79.40	11.71	74	42971	444941	79256402
Device issue	77.48	11.71	84	42961	27024	79674319
Depression	77.28	11.71	275	42770	216515	79484828
Emotional distress	73.48	11.71	99	42946	39870	79661473
Application site swelling	70.24	11.71	23	43022	730	79700613
Application site scar	69.37	11.71	17	43028	180	79701163
Cerebral vasoconstriction	69.04	11.71	27	43018	1443	79699900
Dizziness	67.81	11.71	501	42544	525940	79175403
Chest discomfort	67.28	11.71	195	42850	137849	79563494
Drug ineffective	65.71	11.71	879	42166	1080034	78621309
Cardiac failure	61.85	11.71	6	43039	154836	79546507
Injection site pain	59.07	11.71	179	42866	129659	79571684
Muscle twitching	57.65	11.71	69	42976	24695	79676648
Pituitary tumour benign	57.47	11.71	28	43017	2548	79698795
Post-traumatic neck syndrome	56.66	11.71	26	43019	2068	79699275
Febrile neutropenia	56.49	11.71	27	43018	230972	79470371
Incorrect route of product administration	55.97	11.71	81	42964	34848	79666495
Application site vesicles	55.69	11.71	23	43022	1417	79699926
Concussion	53.57	11.71	43	43002	9460	79691883
Neutropenia	52.26	11.71	47	42998	287663	79413680
Cholecystitis chronic	52.00	11.71	43	43002	9863	79691480
Drug specific antibody	51.05	11.71	26	43019	2602	79698741
Soft tissue injury	50.99	11.71	23	43022	1758	79699585
Hot flush	50.13	11.71	99	42946	54778	79646565
Stress cardiomyopathy	49.51	11.71	44	43001	11122	79690221
Cluster headache	49.28	11.71	19	43026	977	79700366
Chest pain	49.21	11.71	290	42755	282014	79419329
Disease progression	49.13	11.71	19	43026	184343	79517000
Hostility	48.23	11.71	24	43021	2286	79699057
Injection site haemorrhage	48.16	11.71	67	42978	27803	79673540
Clonus	47.42	11.71	35	43010	6805	79694538
Sepsis	46.60	11.71	46	42999	269382	79431961
Nausea	46.43	11.71	749	42296	956447	78744896
Muscle tightness	45.91	11.71	45	43000	12869	79688474
Libido increased	45.39	11.71	22	43023	1979	79699364
Feeling abnormal	45.23	11.71	188	42857	159011	79542332
Renal infarct	44.77	11.71	24	43021	2667	79698676
Pericarditis	44.50	11.71	3	43042	104233	79597110
Swollen tongue	44.07	11.71	81	42964	42489	79658854
Sternal fracture	43.32	11.71	23	43022	2507	79698836
Renal failure	42.63	11.71	28	43017	200940	79500403
Pneumonia	42.31	11.71	198	42847	660048	79041295
Application site dryness	42.28	11.71	12	43033	232	79701111
Vision blurred	41.75	11.71	139	42906	105759	79595584
Product substitution issue	41.61	11.71	53	42992	20203	79681140
Infusion related reaction	41.34	11.71	38	43007	230199	79471144
Pancytopenia	41.09	11.71	19	43026	165726	79535617
Renal impairment	40.83	11.71	17	43028	157766	79543577
Application site exfoliation	40.60	11.71	14	43031	522	79700821
Hyponatraemia	40.20	11.71	23	43022	177825	79523518
Treatment failure	40.06	11.71	21	43024	170465	79530878
Injection site bruising	39.93	11.71	76	42969	40926	79660417
Hyperkalaemia	39.55	11.71	7	43038	114391	79586952
Device power source issue	39.35	11.71	16	43029	947	79700396
Hypoaesthesia	39.17	11.71	196	42849	179156	79522187
Interstitial lung disease	38.68	11.71	7	43038	112593	79588750
Thrombocytopenia	38.61	11.71	52	42993	265207	79436136
Multiple organ dysfunction syndrome	38.16	11.71	9	43036	120237	79581106
Suicidal ideation	37.32	11.71	108	42937	76232	79625111
Angle closure glaucoma	37.19	11.71	22	43023	2954	79698389
Vasospasm	36.83	11.71	16	43029	1118	79700225
Glossodynia	36.43	11.71	6	43039	103331	79598012
Wound	36.27	11.71	9	43036	116170	79585173
Hyperhidrosis	35.55	11.71	169	42876	151323	79550020
Platelet count decreased	35.09	11.71	32	43013	194632	79506711
Swelling face	35.06	11.71	101	42944	71111	79630232
Application site inflammation	34.43	11.71	12	43033	462	79700881
Hypotension	33.81	11.71	123	42922	440194	79261149
Septic shock	32.14	11.71	13	43032	122788	79578555
Lower respiratory tract infection	31.73	11.71	15	43030	129205	79572138
Atrial fibrillation	31.72	11.71	36	43009	197850	79503493
Expired product administered	31.69	11.71	28	43017	7023	79694320
Pharyngeal swelling	31.44	11.71	29	43016	7690	79693653
Tension headache	31.15	11.71	28	43017	7183	79694160
Photophobia	30.57	11.71	46	42999	20482	79680861
Hyperprolactinaemia	30.35	11.71	23	43022	4653	79696690
Malignant neoplasm progression	30.14	11.71	18	43027	135972	79565371
Application site scab	30.03	11.71	9	43036	212	79701131
Pleural effusion	29.78	11.71	21	43024	145241	79556102
Palpitations	29.52	11.71	141	42904	126469	79574874
Gastrointestinal haemorrhage	29.45	11.71	22	43023	147697	79553646
Haemoglobin decreased	28.94	11.71	47	42998	222072	79479271
Hepatic function abnormal	28.75	11.71	3	43042	73104	79628239
Application site reaction	28.68	11.71	12	43033	764	79700579
Off label use	28.57	11.71	333	42712	906882	78794461
Blood creatinine increased	28.53	11.71	25	43020	155032	79546311
Drug hypersensitivity	28.46	11.71	266	42779	298650	79402693
Application site bruise	28.42	11.71	9	43036	256	79701087
Cerebral venous thrombosis	28.39	11.71	18	43027	2735	79698608
Subclavian artery thrombosis	27.94	11.71	6	43039	33	79701310
Tremor	27.86	11.71	172	42873	169911	79531432
General physical health deterioration	27.50	11.71	68	42977	275170	79426173
Systemic lupus erythematosus	26.90	11.71	16	43029	121133	79580210
Secondary adrenocortical insufficiency	26.90	11.71	18	43027	2996	79698347
Pain	26.64	11.71	530	42515	703272	78998071
Nightmare	26.50	11.71	49	42996	25812	79675531
Pharyngeal oedema	26.45	11.71	38	43007	16234	79685109
Pyrexia	26.33	11.71	237	42808	678472	79022871
Somnambulism	26.28	11.71	23	43022	5698	79695645
Product adhesion issue	26.20	11.71	17	43028	2687	79698656
Transient global amnesia	26.05	11.71	12	43033	963	79700380
Vasoconstriction	26.02	11.71	11	43034	719	79700624
Temperature intolerance	25.87	11.71	29	43016	9676	79691667
Respiratory failure	25.77	11.71	36	43009	180875	79520468
Hyperreflexia	25.75	11.71	27	43018	8358	79692985
Arthropathy	25.48	11.71	35	43010	177076	79524267
Application site discomfort	25.29	11.71	9	43036	369	79700974
Personality disorder	24.86	11.71	23	43022	6123	79695220
Incorrect dose administered by device	24.83	11.71	21	43024	4968	79696375
Therapeutic response unexpected	24.60	11.71	41	43004	19905	79681438
Electrocardiogram ST segment elevation	23.96	11.71	26	43019	8371	79692972
Middle insomnia	23.92	11.71	36	43009	16033	79685310
Cardiac failure congestive	23.82	11.71	25	43020	142377	79558966
Contraindicated product administered	23.82	11.71	30	43015	157508	79543835
Decreased appetite	23.49	11.71	100	42945	342318	79359025
Migraine without aura	23.31	11.71	8	43037	294	79701049
Poor quality sleep	23.22	11.71	43	43002	22679	79678664
Drug dependence	23.22	11.71	61	42984	40708	79660635
Injury	23.16	11.71	93	42952	77403	79623940
Product leakage	23.02	11.71	11	43034	959	79700384
Product complaint	22.92	11.71	32	43013	13317	79688026
Pre-existing condition improved	22.85	11.71	21	43024	5542	79695801
Muscle spasms	22.79	11.71	167	42878	174563	79526780
Phonophobia	22.56	11.71	9	43036	507	79700836
Body temperature increased	21.86	11.71	63	42982	44357	79656986
Impaired healing	21.79	11.71	10	43035	87645	79613698
Renal tubular acidosis	21.76	11.71	17	43028	3597	79697746
Infection	21.66	11.71	63	42982	241649	79459694
Device leakage	21.66	11.71	28	43017	10828	79690515
Blood pressure systolic increased	21.28	11.71	5	43040	66981	79634362
Loss of consciousness	21.04	11.71	159	42886	167784	79533559
Meconium in amniotic fluid	20.90	11.71	6	43039	121	79701222
Head discomfort	20.89	11.71	32	43013	14470	79686873
Irritability	20.87	11.71	59	42986	41085	79660258
Hepatic enzyme increased	20.78	11.71	42	43003	182568	79518775
Dysgeusia	20.73	11.71	73	42972	57104	79644239
Neck pain	20.57	11.71	88	42957	75329	79626014
Withdrawal syndrome	20.48	11.71	45	43000	26809	79674534
Brugada syndrome	20.48	11.71	11	43034	1227	79700116
Gallbladder disorder	20.27	11.71	37	43008	19303	79682040
Myofascial pain syndrome	20.21	11.71	13	43032	2024	79699319
Burns third degree	20.01	11.71	8	43037	453	79700890
Burning sensation	19.68	11.71	73	42972	58559	79642784
Flushing	19.63	11.71	97	42948	88171	79613172
Basilar migraine	19.54	11.71	5	43040	64	79701279
Joint swelling	19.36	11.71	85	42960	288561	79412782
Epistaxis	19.30	11.71	19	43026	111496	79589847
Major depression	19.24	11.71	24	43021	8956	79692387
Post-traumatic stress disorder	19.23	11.71	18	43027	4863	79696480
Hyperacusis	19.18	11.71	13	43032	2210	79699133
Xanthelasma	19.14	11.71	6	43039	165	79701178
Migraine with aura	19.11	11.71	14	43031	2691	79698652
Blood bilirubin increased	19.05	11.71	6	43039	66226	79635117
Plasma cell myeloma	18.98	11.71	3	43042	53256	79648087
Meningoradiculitis	18.94	11.71	6	43039	171	79701172
Application site papules	18.93	11.71	5	43040	73	79701270
Device difficult to use	18.53	11.71	29	43016	13356	79687987
Complement factor C4 decreased	18.48	11.71	7	43038	343	79701000
Insomnia	18.46	11.71	208	42837	244962	79456381
Diarrhoea	18.37	11.71	350	42695	880139	78821204
Eyelid ptosis	18.26	11.71	26	43019	11018	79690325
Multiple sclerosis relapse	18.26	11.71	61	42984	46472	79654871
Rheumatoid arthritis	18.19	11.71	55	42990	208415	79492928
Dependence	18.17	11.71	13	43032	2409	79698934
Injection site erythema	18.16	11.71	87	42958	78110	79623233
Aphasia	18.11	11.71	61	42984	46671	79654672
Optic ischaemic neuropathy	17.98	11.71	14	43031	2947	79698396
Complement factor C3 decreased	17.95	11.71	7	43038	371	79700972
Foetal heart rate abnormal	17.85	11.71	7	43038	377	79700966
Ovarian neoplasm	17.72	11.71	8	43037	613	79700730
International normalised ratio increased	17.69	11.71	12	43033	84709	79616634
Memory impairment	17.67	11.71	112	42933	111622	79589721
Biliary dyskinesia	17.59	11.71	13	43032	2532	79698811
Paraesthesia oral	17.58	11.71	36	43009	20435	79680908
Nipple pain	17.52	11.71	9	43036	917	79700426
Gastrooesophageal reflux disease	17.43	11.71	106	42939	104140	79597203
Meningitis aseptic	17.28	11.71	20	43025	6908	79694435
Transverse sinus thrombosis	17.19	11.71	8	43037	657	79700686
Teratogenicity	16.88	11.71	6	43039	245	79701098
Sunburn	16.79	11.71	15	43030	3818	79697525
Tinnitus	16.41	11.71	57	42988	44276	79657067
Superior sagittal sinus thrombosis	16.35	11.71	9	43036	1054	79700289
Injection site laceration	16.29	11.71	5	43040	128	79701215
Application site erosion	16.12	11.71	6	43039	280	79701063
Peripheral coldness	16.04	11.71	30	43015	15940	79685403
Folliculitis	15.96	11.71	5	43040	55375	79645968
Bone marrow failure	15.87	11.71	4	43041	51103	79650240
Hypoglycaemia	15.72	11.71	19	43026	101575	79599768
Abortion spontaneous	15.64	11.71	43	43002	29464	79671879
Hormone level abnormal	15.61	11.71	11	43034	1991	79699352
Visual impairment	15.60	11.71	94	42951	92037	79609306
Seizure	15.50	11.71	163	42882	188671	79512672
Vertigo	15.42	11.71	76	42969	69006	79632337
Oxygen saturation decreased	15.26	11.71	29	43016	129018	79572325
Large intestinal ulcer haemorrhage	15.21	11.71	6	43039	328	79701015
Pancreatic failure	15.20	11.71	10	43035	1618	79699725
Gallbladder injury	15.19	11.71	9	43036	1212	79700131
Toxicity to various agents	15.11	11.71	150	42895	421390	79279953
Inflammation	15.08	11.71	17	43028	93736	79607607
Post viral fatigue syndrome	14.96	11.71	6	43039	343	79701000
Liver injury	14.80	11.71	6	43039	56608	79644735
Lactic acidosis	14.64	11.71	10	43035	70349	79630994
C-reactive protein abnormal	14.61	11.71	4	43041	48363	79652980
Torsade de pointes	14.32	11.71	32	43013	19280	79682063
Neoplasm progression	14.31	11.71	5	43040	51677	79649666
Cerebral venous sinus thrombosis	14.28	11.71	11	43034	2280	79699063
Asthma	14.25	11.71	123	42922	134972	79566371
Incorrect disposal of product	14.22	11.71	8	43037	977	79700366
Illness	14.04	11.71	56	42989	46455	79654888
Acute myocardial infarction	13.95	11.71	80	42965	76956	79624387
Gastrointestinal tract irritation	13.95	11.71	7	43038	679	79700664
Cytomegalovirus infection	13.91	11.71	3	43042	42641	79658702
Dysphonia	13.73	11.71	64	42981	56808	79644535
Peripheral nerve injury	13.68	11.71	7	43038	707	79700636
Pericardial effusion	13.64	11.71	4	43041	46233	79655110
Product dispensing error	13.43	11.71	25	43020	13238	79688105
Anger	13.36	11.71	29	43016	17133	79684210
Hyperglycaemia	13.35	11.71	11	43034	70324	79631019
Stomatitis	13.32	11.71	38	43007	146719	79554624
Product storage error	13.30	11.71	28	43017	16198	79685145
Ischaemic cerebral infarction	13.30	11.71	11	43034	2524	79698819
Injection site injury	13.30	11.71	7	43038	750	79700593
Aspartate aminotransferase increased	13.26	11.71	35	43010	138606	79562737
Haemorrhage	13.10	11.71	18	43027	91100	79610243
Neutrophil count decreased	13.08	11.71	19	43026	93940	79607403
Psoriasis	13.06	11.71	88	42957	89499	79611844
Mucosal inflammation	12.94	11.71	13	43032	75567	79625776
Therapeutic product effect incomplete	12.93	11.71	125	42920	141520	79559823
Injection site urticaria	12.76	11.71	24	43021	12802	79688541
Choking sensation	12.76	11.71	13	43032	3893	79697450
Product use issue	12.76	11.71	64	42981	209758	79491585
Alanine aminotransferase increased	12.72	11.71	45	43000	162525	79538818
Deep vein thrombosis	12.71	11.71	110	42935	120809	79580534
Incorrect product administration duration	12.60	11.71	23	43022	11999	79689344
Panic attack	12.55	11.71	35	43010	24181	79677162
Capillaritis	12.53	11.71	5	43040	282	79701061
Bradycardia	12.38	11.71	35	43010	135522	79565821
Lichen planus	12.38	11.71	11	43034	2780	79698563
Nasal oedema	12.35	11.71	9	43036	1715	79699628
Trismus	12.34	11.71	15	43030	5452	79695891
Multiple sclerosis	12.34	11.71	33	43012	22249	79679094
Hypomagnesaemia	12.22	11.71	5	43040	46906	79654437
Rib fracture	12.20	11.71	38	43007	27909	79673434
Facial pain	12.15	11.71	23	43022	12327	79689016
Somnolence	11.85	11.71	188	42857	238793	79462550
Red blood cell sedimentation rate increased	11.80	11.71	5	43040	45937	79655406
Abdominal discomfort	11.79	11.71	83	42962	250644	79450699
Drug-induced liver injury	11.75	11.71	11	43034	66106	79635237

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N02CC01	NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Selective serotonin (5HT1) agonists
CHEBI has role	CHEBI:35941	serotonin agonists
FDA MoA	N0000175763	Serotonin 1b Receptor Agonists
FDA MoA	N0000175764	Serotonin 1d Receptor Agonists
FDA EPC	N0000175765	Serotonin-1b and Serotonin-1d Receptor Agonist
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D058825	Serotonin 5-HT1 Receptor Agonists
MeSH PA	D018490	Serotonin Agents
MeSH PA	D017366	Serotonin Receptor Agonists
MeSH PA	D014662	Vasoconstrictor Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Migraine	indication	37796009	DOID:6364
Cluster headache syndrome	indication	193031009
Tachyarrhythmia	contraindication	6285003
Alcoholism	contraindication	7200002
Hypercholesterolemia	contraindication	13644009
Myocardial infarction	contraindication	22298006	DOID:5844
Hypertensive disorder	contraindication	38341003	DOID:10763
Gastrointestinal ulcer	contraindication	40845000
Body fluid retention	contraindication	43498006
Chronic heart failure	contraindication	48447003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Hemiplegic migraine	contraindication	59292006
Hepatic failure	contraindication	59927004
Blood coagulation disorder	contraindication	64779008	DOID:1247
Diabetes mellitus	contraindication	73211009	DOID:9351
Gastrointestinal hemorrhage	contraindication	74474003
Vascular insufficiency of intestine	contraindication	82196007
Epilepsy	contraindication	84757009	DOID:1826
Prinzmetal angina	contraindication	87343002
Kidney disease	contraindication	90708001	DOID:557
Liver function tests abnormal	contraindication	166603001
Angina pectoris	contraindication	194828000
Cerebrovascular accident	contraindication	230690007
Coronary artery bypass graft	contraindication	232717009
Disease of liver	contraindication	235856003	DOID:409
Transient ischemic attack	contraindication	266257000	DOID:224
Esophageal dysmotility	contraindication	266434009	DOID:9192
Edema	contraindication	267038008
Anemia	contraindication	271737000	DOID:2355
Cerebral ischemia	contraindication	287731003
Pregnancy, function	contraindication	289908002
Thromboembolic disorder	contraindication	371039008
Serotonin syndrome	contraindication	371089000
Cardiovascular event risk	contraindication	395112001
Peripheral vascular disease	contraindication	400047006
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Hypertensive urgency	contraindication	443482000
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.23	acidic
pKa2	13.42	acidic
pKa3	8.28	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	8327844	Oct. 3, 2023	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	7975690	Aug. 18, 2025	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	8590530	Sept. 15, 2025	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
500MG;EQ 85MG BASE	TREXIMET	CURRAX	N021926	April 15, 2008	RX	TABLET	ORAL	7332183	Oct. 2, 2025	TREATMENT OF MIGRAINE
60MG;EQ 10MG BASE	TREXIMET	CURRAX	N021926	May 14, 2015	DISCN	TABLET	ORAL	7332183	Oct. 2, 2025	ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	11571531	Feb. 23, 2026	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
10MG/SPRAY	TOSYMRA	TONIX MEDS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	8440631	May 9, 2026	ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10124132	March 6, 2027	ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10124132	March 6, 2027	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10124132	March 6, 2027	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	7973058	April 12, 2027	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	8155737	April 12, 2027	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	8470853	April 12, 2027	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	9427578	April 12, 2027	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	ALSUMA	MERIDIAN MEDCL	N022377	June 29, 2010	DISCN	INJECTABLE	SUBCUTANEOUS	7811254	Aug. 26, 2027	ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	8875704	April 7, 2028	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	8366600	April 21, 2029	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10076615	July 30, 2029	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10076615	July 30, 2029	METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10076615	July 30, 2029	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
10MG/SPRAY	TOSYMRA	TONIX MEDS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	10603305	June 16, 2030	ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY	TOSYMRA	TONIX MEDS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	11337962	June 16, 2030	ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY	TOSYMRA	TONIX MEDS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	9610280	June 16, 2030	ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY	TOSYMRA	TONIX MEDS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	9974770	June 16, 2030	ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	9649456	Oct. 21, 2030	ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	9649456	Oct. 21, 2030	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	9649456	Oct. 21, 2030	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	8983594	Nov. 19, 2030	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
10MG/SPRAY	TOSYMRA	TONIX MEDS	N210884	Jan. 25, 2019	RX	SPRAY	NASAL	9211282	July 19, 2031	ACUTE TREATMENT OF MIGRAINE
EQ 6.5MG BASE/4HR	ZECUITY	TEVA BRANDED PHARM	N202278	Jan. 17, 2013	DISCN	SYSTEM	IONTOPHORESIS	9327114	Oct. 8, 2032	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 11MG BASE	ONZETRA XSAIL	CURRAX	N206099	Jan. 27, 2016	RX	POWDER	NASAL	10478574	Nov. 4, 2033	METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	ZEMBRACE SYMTOUCH	TONIX MEDS	N208223	Jan. 28, 2016	RX	SOLUTION	SUBCUTANEOUS	10537554	Jan. 29, 2036	TREATMENT OF MIGRAINE
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	ZEMBRACE SYMTOUCH	TONIX MEDS	N208223	Jan. 28, 2016	RX	SOLUTION	SUBCUTANEOUS	11364224	Jan. 29, 2036	TREATMENT OF MIGRAINE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN	AGONIST	Ki	8.92	CHEMBL	CHEMBL
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN	AGONIST	Ki	8.26	CHEMBL	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		IC50	8.14	CHEMBL
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN	ANTAGONIST	Ki	5.60	IUPHAR
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN	ANTAGONIST	Ki	6	IUPHAR
5-hydroxytryptamine receptor 3A	Ion channel	P46098	5HT3A_HUMAN		IC50	8.03	CHEMBL
5-hydroxytryptamine receptor 5A	GPCR	P47898	5HT5A_HUMAN		IC50	6.30	CHEMBL
5-hydroxytryptamine receptor 1F	GPCR	P30939	5HT1F_HUMAN		Ki	7.59	CHEMBL
5-hydroxytryptamine receptor 1E	GPCR	P28566	5HT1E_HUMAN		IC50	5.26	CHEMBL
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN		IC50	5.17	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.64	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.42	CHEMBL
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	7.64	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	6.19	CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT	ANTAGONIST	Ki	6.60	IUPHAR
5-hydroxytryptamine receptor 1D	GPCR		5HT1D_PIG		IC50	7.70	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_MOUSE		IC50	6.35	CHEMBL
5-hydroxytryptamine receptor 1D	GPCR		5HT1D_RAT		IC50	7.21	CHEMBL
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT	ANTAGONIST	Ki	5.20	IUPHAR
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_GORGO		Ki	8.19	CHEMBL
5-hydroxytryptamine 1D receptor	Unclassified		Q8MI13_BOVIN		IC50	7.23	CHEMBL
5-hydroxytryptamine receptor 5A	GPCR		5HT5A_MOUSE	AGONIST	Ki	4.80	IUPHAR

External reference:

ID	Source
4021050	VUID
N0000148514	NUI
D00451	KEGG_DRUG
103628-48-4	SECONDARY_CAS_RN
4020790	VANDF
4021050	VANDF
C0075632	UMLSCUI
CHEBI:10650	CHEBI
CHEMBL128	ChEMBL_ID
DB00669	DRUGBANK_ID
CHEMBL1201150	ChEMBL_ID
D018170	MESH_DESCRIPTOR_UI
5358	PUBCHEM_CID
54	IUPHAR_LIGAND_ID
6125	INN_ID
8R78F6L9VO	UNII
37418	RXNORM
158892	MMSL
166806	MMSL
25268	MMSL
31925	MMSL
5536	MMSL
d03160	MMSL
004044	NDDF
004045	NDDF
322822007	SNOMEDCT_US
395892000	SNOMEDCT_US
96215002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Sumatriptan	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2013	INJECTION	4 mg	SUBCUTANEOUS	ANDA	28 sections
Sumatriptan	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2013	INJECTION	4 mg	SUBCUTANEOUS	ANDA	28 sections
Sumatriptan	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2014	INJECTION	6 mg	SUBCUTANEOUS	ANDA	28 sections
Sumatriptan	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2014	INJECTION	6 mg	SUBCUTANEOUS	ANDA	28 sections
SUMATRIPTAN	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9638	INJECTION	6 mg	SUBCUTANEOUS	ANDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0478	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0478	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0478	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0479	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0479	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0479	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0523	SPRAY	20 mg	NASAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0523	SPRAY	20 mg	NASAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0524	SPRAY	5 mg	NASAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0524	SPRAY	5 mg	NASAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0735	TABLET, FILM COATED	25 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0735	TABLET, FILM COATED	25 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0736	TABLET, FILM COATED	50 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0736	TABLET, FILM COATED	50 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0737	TABLET, FILM COATED	100 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0737	TABLET, FILM COATED	100 mg	ORAL	NDA	27 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0739	INJECTION	4 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0739	INJECTION	4 mg	SUBCUTANEOUS	NDA	28 sections
IMITREX	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0739	INJECTION	4 mg	SUBCUTANEOUS	NDA	28 sections
ZEMBRACE SYMTOUCH	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0809	INJECTION, SOLUTION	3 mg	SUBCUTANEOUS	NDA	31 sections
ZEMBRACE SYMTOUCH	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0809	INJECTION, SOLUTION	3 mg	SUBCUTANEOUS	NDA	31 sections
TOSYMRA	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0812	SPRAY	10 mg	NASAL	NDA	31 sections
TOSYMRA	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0812	SPRAY	10 mg	NASAL	NDA	31 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5630	TABLET, FILM COATED	25 mg	ORAL	ANDA	28 sections
Sumatriptan Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5630	TABLET, FILM COATED	25 mg	ORAL	ANDA	28 sections